Funding news · Sep 21, 2026
Respiree raises Series A led by ClavystBio for AI-driven disease progression platform
Respiree Closes Series A Led by ClavystBio
Singapore-founded health tech company Respiree has raised a Series A round led by ClavystBio, according to funding data dated September 21, 2026. The round includes a broad syndicate of investors spanning venture capital and strategic partners.
What Respiree Does
Respiree builds AI/ML platforms for managing disease progression across the care continuum. Its 1Bio platform draws on electronic health record data and proprietary US-patented, FDA-cleared sensors to track patient trajectories longitudinally.
The company's solutions are available in the United States, Australia, and the APAC region. Respiree's regulatory footprint includes:
- CE marking
- US FDA 510(k) clearance
- Australia TGA clearance
Respiree is led by founder and CEO Dr. Gurpreet Singh. The company operates from Singapore and maintains a US headquarters at the Texas Medical Center Innovation in Houston.
Funding Details
| Item | Detail |
|---|---|
| Round type | Series A |
| Date | September 21, 2026 |
| Lead investor | ClavystBio |
| Investors | Seeds Capital, Greenwillow Capital Management, ClavystBio, We Venture Capital, Adaptive Capital Partners, ARKRAY & PARTNERS Pte. Ltd. (AAP), Bizedge Capital, One Six 8 Ventures |
The funding amount was not disclosed in the available data.
Investor Syndicate
The Series A brings together a mix of institutional and strategic backers. ClavystBio led the round. Additional participants include Seeds Capital, Greenwillow Capital Management, We Venture Capital, Adaptive Capital Partners, ARKRAY & PARTNERS Pte. Ltd. (AAP), Bizedge Capital, and One Six 8 Ventures.
The presence of ARKRAY & PARTNERS Pte. Ltd. (AAP), a strategic participant, alongside a set of venture funds, suggests a blend of financial and industry-aligned support for Respiree's platform.
Why This Matters for Digital Health
Respiree operates in the longitudinal patient monitoring and disease progression space, where the combination of EHR data and cleared sensor hardware creates a data asset that compounds over time. The company's regulatory clearances across the US, Europe, and Australia give it the ability to commercialize across multiple major markets.
Its dual presence in Singapore and Houston positions it at the intersection of APAC healthcare innovation and the US medical ecosystem, with the Texas Medical Center Innovation providing a base in one of the largest medical complexes in the world.
What to Watch
For acquisition-oriented observers, Respiree represents a regulated digital health asset with patented sensor technology, FDA clearance, and a multi-market commercial footprint. The Series A capital, led by ClavystBio with a syndicate of venture and strategic investors, is positioned to support the next phase of growth.
Key questions going forward include how Respiree scales its 1Bio platform across care settings, how it deepens its US presence from the Houston base, and how its cleared sensor portfolio expands within the longitudinal disease management market.
Summary
- Respiree raised a Series A led by ClavystBio, dated September 21, 2026.
- The company is a Singapore-founded health tech firm led by founder and CEO Dr. Gurpreet Singh.
- Its 1Bio platform uses EHR data and US-patented, FDA-cleared sensors to track patient trajectories.
- Solutions are available in the US, Australia, and APAC, with CE marking, FDA 510(k), and TGA clearances.
- The investor syndicate includes Seeds Capital, Greenwillow Capital Management, We Venture Capital, Adaptive Capital Partners, ARKRAY & PARTNERS Pte. Ltd. (AAP), Bizedge Capital, and One Six 8 Ventures.